GetTopicDetailResponse(id=747e81e1a1, topicName=Golimumab, introduction=Golimumab, content=null, image=null, comments=4, allHits=1207, url=https://h5.medsci.cn/topic?id=8171, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=40049, tagList=[TagDto(tagId=40049, tagName=Golimumab)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1720711, encodeId=ce841e2071109, content=<a href='/topic/show?id=747e81e1a1' target=_blank style='color:#2F92EE;'>#Golimumab#</a>, objectTitle=NEJM：Golimumab可部分恢復(fù)新發(fā)病I型糖尿病青年患者的胰島功能, objectType=article, longId=203558, objectId=5ef12035588c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ef12035588c, replyNumber=0, likeNumber=122, createdTime=2021-10-03, rootId=0, userName=gostraight, userId=9b7232942771, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ef12035588c, moduleTitle=NEJM：Golimumab可部分恢復(fù)新發(fā)病I型糖尿病青年患者的胰島功能, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=5ef12035588c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720710, encodeId=d6dd1e2071028, content=<a href='/topic/show?id=747e81e1a1' target=_blank style='color:#2F92EE;'>#Golimumab#</a>, objectTitle=強(qiáng)生向美國(guó)FDA提交兩份申請(qǐng)，申請(qǐng)批準(zhǔn)golimumab治療少年特發(fā)性關(guān)節(jié)炎和銀屑病關(guān)節(jié)炎, objectType=article, longId=193032, objectId=cd3e1930322e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd3e1930322e, replyNumber=0, likeNumber=103, createdTime=2020-10-13, rootId=0, userName=gostraight, userId=9b7232942771, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd3e1930322e, moduleTitle=強(qiáng)生向美國(guó)FDA提交兩份申請(qǐng)，申請(qǐng)批準(zhǔn)golimumab治療少年特發(fā)性關(guān)節(jié)炎和銀屑病關(guān)節(jié)炎, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=cd3e1930322e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720709, encodeId=a8fa1e207093a, content=<a href='/topic/show?id=747e81e1a1' target=_blank style='color:#2F92EE;'>#Golimumab#</a>, objectTitle=Inflam Bowel Dis： Golimumab的連續(xù)臨床反應(yīng)與重度潰瘍性結(jié)腸炎患者病程變化相關(guān), objectType=article, longId=157181, objectId=341f15e18134, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=341f15e18134, replyNumber=0, likeNumber=91, createdTime=2019-11-21, rootId=0, userName=gostraight, userId=9b7232942771, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=341f15e18134, moduleTitle=Inflam Bowel Dis： Golimumab的連續(xù)臨床反應(yīng)與重度潰瘍性結(jié)腸炎患者病程變化相關(guān), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=341f15e18134)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720708, encodeId=4e3e1e20708d0, content=<a href='/topic/show?id=747e81e1a1' target=_blank style='color:#2F92EE;'>#Golimumab#</a>, objectTitle=Golimumab治療外周型SpA的療效評(píng)估, objectType=article, longId=82470, objectId=fc66824e015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc66824e015, replyNumber=0, likeNumber=91, createdTime=2017-08-17, rootId=0, userName=gostraight, userId=9b7232942771, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc66824e015, moduleTitle=Golimumab治療外周型SpA的療效評(píng)估, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=fc66824e015)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
